KRAS and pancreatic ductal adenocarcinoma: In pancreatic ductal adenocarcinoma (PDAC), disruption of the KRAS-HSL axis resulted in decreased lipid storage, tumor cell metabolic reprogramming, and reduced invasive and metastatic ability, indicating that the KRAS-HSL axis is a potential therapeutic target for PDAC [86].